[5] Under his leadership Allergan grew from a small eye care business to an international pharmaceutical and medical device company that earns over $5 billion a year.
[30] Pyott and Allergan, standing tall on their beliefs, rejected the offer citing yet again Valeant's unsustainable business model.
In order to ward off the hostile takeover attempt, Allergan was courting other offers from companies with more sustainable business models.
[32] On November 17, 2014, Allergan announced that they had agreed to a deal with Actavis plc for $66 billion, making it one of the world's largest drug makers by sales.
[32] Pyott's decision to move forward with Actavis was based on the company's impressive management structure and desire to keep more of Allergan's research and development operation intact.
[32] After the acquisition was finalized, Pyott elected not to join the combined company's board, but stayed on as chairman of The Allergan Foundation for a year.
[35] A number of factors contributed to the collapse of Valeant, many of which validate Pyott's approach to business.
[38][39] Throughout his career, Pyott has collected a number of honors and awards for his philanthropic efforts and his leadership at Allergan.